First diet | Vegan supplemented | With protein- free food | Other | All cases | p Among groups |
---|---|---|---|---|---|
n | 215 | 159 | 75 | 449 | Â |
Males (%) | 144 (67.0%) | 98 (61.6%) | 34 (45.3%) | 276 (61.5%) | 0.004 |
Females (%) | 71 (33.0%) | 61 (38.4%) | 41 (54.7%) | 173 (38.5%) | |
Age: median (min-max) | 65 (19–86) | 76 (26–97) | 71 (23–88) | 70 (19–97) | <0.001 |
Age over 65 (%) | 100 (46.5%) | 132 (83%) | 42 (56%) | 274 (61%) | <0.001 |
Age over 80 (%) | 15 (7.0%) | 44 (27.7%) | 14 (18.7%) | 73 (16.3%) | <0.001 |
Charlson: median (min-max) | 6 (2–12) | 8 (2–13) | 6 (2–12) | 7 (2–13) | <0.001 |
Charlson > =7 (%) | 91 (42.3%) | 118 (74.2%) | 37 (49.3%) | 246 (54.8%) | <0.001 |
Charlson > =10 (%) | 17 (7.9%) | 42 (26.4%) | 12 (16.0%) | 71 (15.8%) | <0.001 |
Diabetes (%) | 59 (27.4%) | 70 (44%) | 20 (26.7%) | 149 (33.2%) | 0.001 |
Cardiopathy (%) | 79 (36.7%) | 100 (62.9%) | 29 (38.7%) | 208 (46.3%) | <0.001 |
Neoplasia (%) | 41 (19.1%) | 33 (20.8%) | 23 (30.7%) | 97 (21.6%) | 0.104 |
sCreatinine (mg/dL) median (min-max) | 3.05 (0.6–16) | 2.65 (1.0–7) | 2.49 (0.6–6.7) | 2.8 (0.6–16) | <0.001 |
eGFR-EPI (mL/min) median (min-max) | 18.9 (3–126) | 20.5 (6.6–73) | 22.5 (5.7–127) | 20.0 (3–127) | 0.014 |
GFR <15Â mL/min at enrolment n (%) | 80 (37.6%) | 32 (20.1%) | 13 (17.3%) | 125 (28%) | <0.001 |
GFR <10Â mL/min at enrolment n (%) | 29 (13.6%) | 10 (6.3%) | 5 (6.7%) | 44 (9.8%) | 0.038 |
Proteinuria (g/day) median (min-max) | 1.2 (0.1–10) | 0.3 (0.1–7) | 0.9 (0.1–11) | 0.8 (0.1–11) | <0.001 |
Proteinuria > = 1 g/day (%) | 125 (58.7%) | 41 (26.1%) | 36 (48.0%) | 202 (45.4%) | <0.001 |
Proteinuria > = 3 g/day (%) | 50 (23.5%) | 18 (11.5%) | 14 (18.7%) | 82 (18.4%) | 0.013 |
Glomerulonephritis-systemic disease (%) | 67 (31.2%) | 12 (7.5%) | 16 (21.3%) | 95 (21.2%) | <0.001 |
Nephroangiosclerosis and/or diabetes (%) | 100 (46.5%) | 128 (80.5%) | 37 (49.3%) | 265 (59.0%) | <0.001 |
ADPKD (%) | 13 (6.0%) | 4 (2.5%) | 7 (9.3%) | 24 (5.3%) | 0.079 |